

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 - 13. (Cancelled)

Claim 14. (Previously Presented): A process for the preparation of donepezil hydrochloride monohydrate characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 5.0, 10.0, 12.7, 13.2, 16.2, 20.0, 21.3, 23.1, 23.9 and 25.3 degrees, which comprises the steps of: a) dissolving donepezil free base in a mixture of chloroform and water; b) adding hydrochloric acid; and c) precipitating donepezil hydrochloride monohydrate from the solution formed in (b) by adding an anti-solvent.

Claim 15. (Previously Presented): The process according to claim 14, wherein the anti-solvent is diisopropyl ether, n-hexane, n-heptane or diethyl ether.

Claim 16. (Previously Presented): The process according to claim 14, wherein the anti-solvent is diisopropyl ether.

Claim 17. (Previously Presented): A process for preparation of donepezil hydrochloride monohydrate -characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 5.0, 10.0, 12.7, 13.2, 16.2, 20.0, 21.3, 23.1, 23.9 and 25.3 degrees, which comprises the steps of: a) dissolving donepezil hydrochloride in a mixture of chloroform and water; and b) precipitating donepezil hydrochloride monohydrate from the solution formed in (a) by adding an anti-solvent.

Claim 18. (Previously Presented): The process according to claim 17, wherein the anti-solvent is diisopropyl ether, n-hexane, n-heptane or diethyl ether.

Claim 19. (Previously Presented): The process according to claim 17, wherein the anti-solvent is

Application No. 10/511,735
Amendment Dated 3/10/2009
Reply to Office Action of 01/15/2009

diisopropyl ether.

Claims 20 - 27. (Cancelled)